Women health diseases have increased due to a number of genetic and enviroment related factors. Focused market reports linked with the healthcare industry among others recently have been made available by Market Research Future which issues reports on this industry. The market is set to achieve high levels of revenue while growing with a strong CAGR percent in the forecast period.
Increased cognizance of women’s health issues and disorders has given way to massive developments in the market. The major influencers for change in the market are pharmaceutical companies and wellness groups that are introducing new products and treatments methods to provide a solution to the ailments experienced by women. The establishment of a proper healthcare structure has also enabled the addressing of other women healthcare issues apart from diseases. Issues like pregnancy, menopause have also emerged as strong contributing segments which are likely to boost the development of the market in the forecast period.
Global Competitive Analysis
The stimulus for the market’s growth has changed the competitive backdrop of the market. By making certain supply and demand are in balance, the competitors can reveal new opportunities for growth. The prominent trends and players have led to a positive tone for development. The important trends and players have established a positive tone for development. The prospects for growth and innovation have amplified at a rapid pace transforming the market. Engaging and converting prospective opportunities is modifying the growth pace of the market considerably. The competitors in the market have been encouraged to plan strategic road-maps that capitalize on the positive market cues.
General Electric Company (UK), CooperSurgical Inc. (US), Ascend Therapeutics US, LLC. (US), Rinovum Women's Health, LLC. (US), HRA Pharma and others are a few of the important competitors in the market.
Industry Updates:
May 2018 Lupin which is among major pharma companies has launched a Solosec which is a specialty drug which contains an antimicrobial agent to remedy gynecologic infection among adult women in the US. The drug is generically called as secnidazole 2g oral granules. Solosec received approval in September last year from the US FDA. It is the first antibiotic pill in the market in more than a decade to treat bacterial vaginosis (BV) which among the most common vaginal infection in the US in women of childbearing age. The drug which is cleared for at least ten years of marketing exclusivity in the US as a single dose oral regimen removing the patient’s problem to take multiple pills in a day and increasing compliance to the treatment. The drug is estimated to hit peak sales of USD 100 million per annum in coming four years. The drug became Lupin's asset after it bought Symbiomix Therapeutics for USD 150 million, in a bid to increase its women’s health segment.
No comments:
Post a Comment